Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 0.73 |
| ▸ | HTR7 | P34969 | 3/20 | 0.73 |
| ▸ | HTR6 | P50406 | 3/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9373922 | 0.99 | HTR2A (0.98) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9375390 | 0.99 | HTR2A (0.98) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Oxalic Acid SCHEMBL467239 | 0.98 | HTR2A (0.95) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9374754 | 0.98 | HTR2A (0.95) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1582470 | 0.91 | HTR2A (0.87) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7368435 | 0.91 | HTR2A (0.83) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7418228 | 0.90 | HTR2A (0.85) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7252912 | 0.87 | HTR2A (0.77) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9650868 | 0.86 | HTR2A (0.82) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27497536 | 0.84 | HTR2A (0.72) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254579-B1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | ESTEVE LABOR DR (ES) | 2018-01-10 | — | — | EP | claimed |
| EP-1781272-B1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECHANICAL ALLODYNIA | ESTEVE LABOR DR (ES) | 2017-09-06 | — | — | EP | claimed |
| US-20080194631-A1 | Medicament For the Treatment of Central Nervous System Disorders | KEY OBS (FR) | 2008-08-14 | — | — | US | claimed |
| EP-1773306-A1 | MEDICAMENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Greenpharma (FR) | 2007-04-18 | — | — | EP | claimed |
| WO-2006018538-A1 | MEDICAMENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | GREENPHARMA (FR) | 2006-02-23 | — | — | WO | claimed |
| EP-1436258-A4 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | UNIV EMORY (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | EMORY UNIVERSITY | 2004-07-15 | — | — | US | claimed |
| EP-1436258-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | Emory University (US) | 2004-07-14 | — | — | EP | claimed |
| WO-2002072542-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | EMORY UNIVERSITY (US) | 2002-09-19 | — | — | WO | claimed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| EP-0294183-B1 | Use of ethylamine derivatives as antihypertensive agents | AJINOMOTO KK (JP) | 1994-03-30 | — | — | EP | claimed |
| EP-0294183-A1 | Use of ethylamine derivatives as antihypertensive agents | AJINOMOTO CO., INC. (JP) | 1988-12-07 | — | — | EP | claimed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| EP-0294183-B1 | Use of ethylamine derivatives as antihypertensive agents | AJINOMOTO KK (JP) | 1994-03-30 | — | — | EP | disclosed |
| US-5231105-A | Ethylamine derivatives and antihypertensives containing the same | AJINOMOTO CO., INC. (JP) | 1993-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | HTR2A 4515/4885KDM4E 1669/4885CYP1A2 4732/4885 |
| US-20040138502-A1 | Ph-dependent nmda receptor antagonists | GRIN1, GRIN2B, GRIN3A | HTR2A 679/4885KDM4E 1244/4885CYP1A2 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.